Parkinson's Patient Pathway

I BRAKE FOR MOMENTS,
NOT FOR PARKINSON’S.

Add NOURIANZ®, the only treatment for “off” episodes that lifts the brake of adenosine, to help you brake for what matters to you.
About NOURIANZ
Actor Portrayals.

A different approach to treating “off” time

As Parkinson’s disease (PD) progresses, you may experience “off” time. “Off” time is when a patient’s medications for PD are not working well, which can mean that PD symptoms return. You might wonder what other options you may have for treating your “off” time.

If you have already been prescribed NOURIANZ by your physician or are just thinking about it as a possible treatment, understand that NOURIANZ is a different type of medicine that seems to work in a different way.

NOURIANZ is a prescription medicine used with levodopa and carbidopa to treat adults with PD who are having “off” episodes.

Talk to your doctor to find out if NOURIANZ is right for you.

Branded resources

Explore educational resources, tools, and branded materials to help you manage each day.

 

What is NOURIANZ?

NOURIANZ is a prescription medicine used with levodopa and carbidopa to treat adults with Parkinson’s disease (PD) who are having “off” episodes.

Before you take NOURIANZ, tell your healthcare provider about all your medical conditions, including if you:

  • have a history of abnormal movement (dyskinesia)
  • have a history of psychotic thinking or behavior
  • have reduced liver function
  • smoke cigarettes or use other tobacco products
  • are pregnant or plan to become pregnant. NOURIANZ may harm your unborn baby
  • are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NOURIANZ and other medicines may affect each other causing side effects. NOURIANZ may affect the way other medicines work, and other medicines may affect how NOURIANZ works.

What are the possible side effects of NOURIANZ?
NOURIANZ may cause serious side effects, including:

  • uncontrolled sudden movements (dyskinesia). Uncontrolled sudden movements is one of the most common side effects.
  • hallucinations and other symptoms of psychosis. NOURIANZ can cause abnormal thinking and behavior, including:
    • being overly suspicious or feeling people want to harm you (paranoid ideation)
    • believing things that are not real (delusions)
    • seeing or hearing things that are not real (hallucinations)
    • confusion
    • increased activity or talking (mania)
    • disorientation
    • aggressive behavior
    • agitation
    • delirium (decreased awareness of things around you)
  • unusual urges (impulse control or compulsive behaviors). Some people taking NOURIANZ get urges to behave in a way unusual for them. Examples of this are unusual urges to gamble, increased sexual urges, strong urges to spend money, binge eating, and the inability to control these urges.

If you notice or your family notices that you are developing any new or unusual symptoms or behaviors, talk to your healthcare provider.

The most common side effects of NOURIANZ include uncontrolled movements (dyskinesia), dizziness, constipation, nausea, hallucinations, and problems sleeping (insomnia).

These are not all the possible side effects of NOURIANZ.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

Please see Patient Information for NOURIANZ.

Reference: 1. NOURIANZ [package insert]. Kyowa Kirin, Inc., Bedminster, NJ, USA.

References: 1. Hickey P, Stacy M. Available and emerging treatments for Parkinson’s disease: a review. Drug Des Devel Ther. 2011;5:241-254. 2. The voice of the patient: Parkinson’s disease. Silver Spring, MD: US Food and Drug Administration; April 2016. https://www.fda.gov/media/124392/download. Accessed June 11, 2019. 3. Parkinson’s Foundation. Statistics. https://parkinson.org/Understanding-Parkinsons/Statistics. Accessed May 5, 2019. 4. Stocchi F, Antonini A, Barone P, et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord. 2014;20(2):204-211. 5. NOURIANZ [package insert]. Kyowa Kirin, Inc., Bedminster, NJ, USA.

References: 1. Data on file. 2. NOURIANZ [package insert]. Kyowa Kirin, Inc., Bedminster, NJ, USA.

Reference: 1. NOURIANZ [package insert]. Kyowa Kirin, Inc., Bedminster, NJ, USA.